Seminars in Oncology
Volume 35, Issue 6 , Pages 597-617, December 2008

Management of Prostate Cancer in the Older Man

  • Supriya G. Mohile

      Affiliations

    • James Wilmot Cancer Center, University of Rochester, Rochester, NY
    • Corresponding Author InformationAddress correspondence to Supriya Gupta Mohile, MD, MS, 601 Elmwood Ave, Box 704, Rochester, NY 14642
  • ,
  • Mark Lachs

      Affiliations

    • Division of Geriatrics, Weill-Cornell Medical College, New York, NY
  • ,
  • William Dale

      Affiliations

    • Department of Medicine, Section of Geriatrics, The University of Chicago, Chicago, IL

Due to the high incidence and prevalence in older men, prostate cancer is best understood as an age-associated disease. Physicians and their older patients commonly face the dilemma of whether or not to initiate treatment for localized disease or early systemic relapse (ie, biochemical recurrence). Although many older men with symptomatic advanced prostate cancer benefit from hormonal treatments and chemotherapies, treatment complications also may influence outcome. Older prostate cancer patients have a high prevalence of other factors that can limit remaining life expectancy (RLE), quality of life (QOL), and tolerance to treatment. A comprehensive geriatric assessment (CGA) can help identify other health status issues that can predict morbidity or mortality in vulnerable or frail older prostate cancer populations. Despite a growing body of evidence, more research is needed to establish optimal treatment strategies for all disease stages in prostate cancer patients diagnosed later in life.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by a Hartford Geriatrics Health Outcomes Research Award (S.G.M.) and a Paul Beeson Career Development Award (W.D.).

PII: S0093-7754(08)00186-3

doi:10.1053/j.seminoncol.2008.08.003

Seminars in Oncology
Volume 35, Issue 6 , Pages 597-617, December 2008